HIVE Blockchain Becomes a Limited Partner in Alpha Sigma Capital Fund
HIVE Invested into Alpha Sigma Capital’s Flagship Multi-Strategy Fund Focused on Investing in Leading Blockchain Companies
Alpha Sigma Capital (ASC), a pioneering digital asset fund focused on the blockchain economy and the shift to a decentralized Web3 infrastructure announced the investment of HIVE Blockchain Technologies Ltd. into its flagship fund launched in January of 2020. The fund invests in companies and decentralized projects that are leveraging blockchain technology to provide demonstrable change and efficiency in financial services, artificial intelligence, supply chain, and biotechnologies. Alpha Sigma Capital utilizes a rigorous fundamental research approach in determining value and managing risk. Under ASC’s Special Situations team, opportunities are examined from value-investing to distressed assets combined with deal structuring that includes mergers and acquisitions, restructuring, consolidation, and public offerings of both utility tokens and equities.
Recommended AI News: Celsius Partners With iHeartMedia In New Podcast Deal
HIVE Blockchain Technologies Ltd. the first publicly listed blockchain infrastructure company that bridges blockchain and cryptocurrencies to traditional capital markets has made an investment into the Alpha Sigma Capital Fund, LP.
Recommended AI News: NEC Payments Finds A New Path To Payment Security With Netcetera
HIVE owns state-of-the-art green energy-powered data centre facilities, which produce newly minted digital currencies like Bitcoin and Ethereum continuously on the cloud. HIVE deployments provide shareholders with exposure to the operating margins of digital currency mining as well as a portfolio of crypto-coins. HIVE has also joined forces with Elon Musk and Michael Saylor, CEO of Microstrategy to form the Bitcoin Mining Council. Which is focused on renewable energy in the cryptocurrency space.
Recommended AI News: Philips And Elekta Deepen Strategic Partnership In Precise And Individualized Oncology Care
Comments are closed.